Transaction · 0001193125-26-424317
CRSPCRISPR Therapeutics AG
George Simeon
George Simeon, DIR, reported an open-market or private sale at CRISPR Therapeutics AG involving 14514.000000 shares for an estimated $720373.36. Reported holdings after the transaction were 15486.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Open-market sellSEC transaction code SDIR
- Trade date
- Oct 14, 2026
- Filing date
- Oct 16, 2026
How reported position traded is calculated
Shares sold ÷ (holdings after + shares sold). Estimated position before: 30,000 shares.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
CRSP price since this filing
Daily closing prices, with the filing date and available return windowsCRSP · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago +6.3%1d ago +1.7%
Returns since7d30d90d180d1y
Transaction facts
Stored Form 4 columns with their raw values
- Type
- Sell Code S
- Identifier
- 0001193125-26-424317 Common Shares
- Transaction date
- Oct 14, 2026 Filed Oct 16, 2026, 09:45 PM · 2d delay
- Shares
- 14,514 sh $49.63 per share
- Estimated value
- -$720k Computed from shares × price
- Holdings after
- 15,486 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Selling Direct Ownership Large Holdings Reduction 10b5-1 Detected
Filing-only score
0 points
Compact filing score computed from stored Form 4 facts. Version v1.
Neutral filing signal
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 2
Filing reported within two business days of the transaction. - tenb5_1_detected-10 points
is_10b5_1 = true
Stored filing content includes detected 10b5-1 language.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Reported roles
No officer title
Officer NoDirector Yes10% NoOther No
Footnotes & amended
- F1
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
- F2
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.45 to $50.44 per share, inclusive. The Reporting Person undertake…
- F3
The Reporting Person is the sole managing member of SR One Capital Management, LLC ("SR One Capital Management"), which is the sole general partner of SR One Capital Partners II, LP ("SR One Partners…
- F4
The Reporting Person is the sole managing member of SR One Capital Management, which is the sole general partner of SR One Capital Opportunities Partners I, LP ("SR One Opportunities Partners I"). SR…
- F5
The Reporting Person is the sole managing member of SR One Capital Management, which is the sole general partner of SR One Capital SMA Partners, LP ("SMA Partners"). SMA Partners is the sole general p…
- F6
This option was granted on October 18, 2016 with respect to 30,000 Common Shares with 100% of the shares vesting in 36 equal monthly installments beginning October 31, 2016.
Related transactions
Same SEC filing0 other transactions
Recent company activity
CRSP0 recent txs